The SGLT2 Inhibitor Empagliflozin Ameliorates the Inflammatory Profile in Type 2 Diabetic Patients and Promotes an Antioxidant Response in Leukocytes - Iannantuoni, F; de Marañon, AM; Diaz-Morales, N (J Clin Med, 2019)